To estimate the incremental cost‐effectiveness of the first‐line pharmacotherapies (nicotine gum, patch, spray, inhaler, and bupropion) for smoking cessation across six Western countries—Canada, France, Spain, Switzerland, the United States, and the United Kingdom
.svg%3Fwidth%3D300&w=3840&q=75)
Aims: Clinical smoking cessation interventions have been found typically to be highly cost-effective...
AbstractPurposeEvaluating the cost-effectiveness of a first-line smoking cessation drug using an ele...
AIMS: To assess the cost-effectiveness of alternative smoking cessation scenarios from the perspect...
To estimate the incremental cost‐effectiveness of the first‐line pharmacotherapies (nicotine gum, pa...
Background: Nicotine dependence is the major obstacle for smokers who want to quit. Guidelines have ...
INTRODUCTION: Public policies for smoking cessation are mainly based on advice from the primary care...
Objectives: To estimate the cost-effectiveness of five face-to-face smoking cessation interventions ...
Objectives: To estimate the cost-effectiveness of five face-to-face smoking cessation interventions:...
AbstractObjectivesTo estimate the cost-effectiveness of five face-to-face smoking cessation interven...
Cost-effectiveness analysis, even with its inherent methodological problems, consistently shows that...
Background: Randomized efficacy clinical trials conducted in research settings may not accurately re...
To evaluate the relative cost-effectiveness of nicotine replacement therapy (NRT) and bupropion SR f...
To evaluate the relative cost-effectiveness of nicotine replacement therapy (NRT) and bupropion SR f...
To evaluate the relative cost-effectiveness of nicotine replacement therapy (NRT) and bupropion SR f...
INTRODUCTION Tobacco cigarette taxes aim at reducing smoking, but smokers are still dependent on ...
Aims: Clinical smoking cessation interventions have been found typically to be highly cost-effective...
AbstractPurposeEvaluating the cost-effectiveness of a first-line smoking cessation drug using an ele...
AIMS: To assess the cost-effectiveness of alternative smoking cessation scenarios from the perspect...
To estimate the incremental cost‐effectiveness of the first‐line pharmacotherapies (nicotine gum, pa...
Background: Nicotine dependence is the major obstacle for smokers who want to quit. Guidelines have ...
INTRODUCTION: Public policies for smoking cessation are mainly based on advice from the primary care...
Objectives: To estimate the cost-effectiveness of five face-to-face smoking cessation interventions ...
Objectives: To estimate the cost-effectiveness of five face-to-face smoking cessation interventions:...
AbstractObjectivesTo estimate the cost-effectiveness of five face-to-face smoking cessation interven...
Cost-effectiveness analysis, even with its inherent methodological problems, consistently shows that...
Background: Randomized efficacy clinical trials conducted in research settings may not accurately re...
To evaluate the relative cost-effectiveness of nicotine replacement therapy (NRT) and bupropion SR f...
To evaluate the relative cost-effectiveness of nicotine replacement therapy (NRT) and bupropion SR f...
To evaluate the relative cost-effectiveness of nicotine replacement therapy (NRT) and bupropion SR f...
INTRODUCTION Tobacco cigarette taxes aim at reducing smoking, but smokers are still dependent on ...
Aims: Clinical smoking cessation interventions have been found typically to be highly cost-effective...
AbstractPurposeEvaluating the cost-effectiveness of a first-line smoking cessation drug using an ele...
AIMS: To assess the cost-effectiveness of alternative smoking cessation scenarios from the perspect...
DOI
Add to ORKG